No retraction, correction or concern found when last checked on Oct 21, 2026.
The Macrophage: A Disputed Fortress in the Battle against Mycobacterium tuberculosis
Christophe J. Queval, Roland Brosch, Roxane Simeone
Frontiers in Microbiology · 2017 · Review
Abstract
Mycobacterium tuberculosis (Mtb), the etiological agent of human tuberculosis (TB), has plagued humans for thousands of years. TB still remains a major public health problem in our era, causing more than 4,400 deaths worldwide every day and killing more people than HIV. After inhaling Mtb-contaminated aerosols, TB primo-infection starts in the terminal lung airways, where Mtb is taken up by alveolar macrophages. Although macrophages are known as professional killers for pathogens, Mtb has adopted remarkable strategies to circumvent host defenses, building suitable conditions to survive and proliferate. Within macrophages, Mtb initially resides inside phagosomes, where its survival mostly depends on its ability to take control of phagosomal processing, through inhibition of phagolysosome biogenesis and acidification processes, and by progressively getting access to the cytosol. Bacterial access to the cytosolic space is determinant for specific immune responses and cell death programs, both required for the replication and the dissemination of Mtb. Comprehension of the molecular events governing Mtb survival within macrophages is fundamental for the improvement of vaccine-based and therapeutic strategies in order to help the host to better defend itself in the battle against the fierce invader Mtb. In this mini-review, we discuss recent research exploring how Mtb conquers and transforms the macrophage into a strategic base for its survival and dissemination as well as the associated defense strategies mounted by host.
Full text
From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.
Introduction
With over a billion deaths in the past 200 years, tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) likely killed more people than any other infectious disease in the history of humanity and remains a major cause of death also in our era. Mtb is responsible for about 10 millions of new TB cases and 1.8 million deaths in 2015. Estimations based on immunological tests suggest that about 2 billion people might be latently infected by Mtb. Statistically, 5–10% of latently infected individuals might then further develop active TB during their lifetime. TB primary infection occurs through inhalation of Mtb-containing aerosol droplets released by contagious individuals. After inhalation, Mtb rapidly reaches the lung’s alveolar space where it is preferentially taken up by alveolar macrophages. Following macrophage phagocytosis, mycobacterial invaders deploy an army of factors, which circumvent macrophage defenses, to escape from macrophage killing and to replicate within these phagocytes. Manipulation of intracellular macrophage signaling also impacts the cytokine environment modifying the potency of protective immune response, setting up a Mtb tolerance by the host and favoring the intracellular survival of Mtb over time. Innate immune responses are essential for the outcome of TB infection as well as for the establishment of adaptive immunity. In lungs, the progressive establishment of an immune response during Mtb infection notably contributes to the aggregation of immune cells, forming an organized structure harboring macrophages at the center, surrounded by giant cells, T-lymphocytes, neutrophils, fibroblast, which is called a granuloma. A hallmark feature of the bacillus is its ability to remain concealed within host cells or/and within the granulomatous caseous necrotic centers, where it can persist during the long phase of TB latency. Establishment of an immune balance, orchestrated by both mycobacteria and host cells, is decisive for the outcome of the granuloma, which may either constrain the infection or promote its systemic dissemination. The development of active pulmonary TB is tightly linked with a disordered immune balance, resulting in host’s inability to keep the infection under control.
The current TB drug regimen generally requires 2-months of treatment with four first-line drugs: isoniazid, rifampicin, ethambutol, and pyrazinamide followed by 4 months of treatment with isoniazid and rifampicin. However, the protracted nature of the TB treatment and an inappropriate patient compliance favor the selection of multidrug resistant strains (MDR-TB). The more recent emergence of extensively drug resistant strains (XDR-TB) represents, nowadays, a major threat. Therefore, new and alternative means to control Mtb are urgently needed. A better understanding of the fundamental biology of this complex interaction of the bacterium and the host cell represents a challenge for the design of new strategies to improve control of TB.
This mini-review focuses on selected aspects of this host-pathogen interaction, which shows quite some resemblance to medieval battlegrounds, where fierce warriors tried to invade well-equipped fortresses with their weapons and ruses.
Mycobacterial Artillery
Mycobacterium tuberculosis belongs to the phylum Actinobacteria and is coated by a unique cell envelope, which represents a remarkably impermeable and hydrophobic armor that is composed of a capsule, an outer membrane, also termed mycomembrane, a peptidoglycan layer, an arabinogalactan layer, and an inner plasma membrane. The mycomembrane consists of mycolic acids and selected extractible lipids, including phthiocerol dimycocerosates (abbreviated DIM or PDIM), diacyltrehalose (DAT), and polyacyltrehalose (PAT). Additionally, Mannosyl-phosphatidyl-myo-inositol-based glycolipids (PIM) and related lipoglycans such as lipomannan (LM) and lipoarabinomannan (LAM) are also abundantly present in the Mtb cell envelope as well as in the inner and outer membranes. To ensure protein transport across this unusual cell envelope Mtb uses different secretion systems, some of which are also widely present in other bacteria, such as the general Sec systems and the Twin Arginine Translocation (TAT) pathway, whereas others are exclusively present in mycobacteria and in some distantly related versions in other species within the phyla Actinobacteria and Firmicutes. These latter systems are called ESX secretion systems and are also known as Type VII secretion (T7S) systems. The Mtb genome carries 5 esx loci, which encode for 5 distinct systems (ESX-1-ESX-5). The molecular architecture of a representative ESX model (ESX-5 of Mycobacterium xenopi) was recently determined at 13Å resolution by electron microscopy. This work showed four core proteins of the ESX-5 complex (EccB5, EccC5, EccD5, and EccE5), which assembled with equimolar stoichiometry into an oligomeric complex that displays sixfold symmetry. Among the ESX systems, the esx-1 locus is probably the most studied as it encodes the 6 kDa Early Secretory Antigenic Target (ESAT-6; EsxA) and the 10 kDa Culture Filtrate Protein (CFP-10; EsxB), considered as key virulence determinants of Mtb as well as strong T-cell antigens. Recent work has shown a concerted action of the ESX-1 secretion system of Mtb with DIM/PDIM in phagosomal rupture, leading to access of Mtb to the cytosol of the host macrophage, a phenomenon recently discussed from different perspectives and described further below.
Doorways of Mtb to Enter Into Macrophages
Interaction of Mtb with phagocytic cells mostly occurs through the recognition of Pathogen-Associated Molecular Patterns (PAMP) present at the bacterial surface by Pattern Recognition Receptors (PRRs) of the host cell such as Toll-Like Receptors (TLR), C-type Lectin Receptors (abbreviated as CLR or CTL), Fc Receptors (FcR), Scavenger Receptors (SR), and cytosolic DNA sensors. Stimulation of PRRs leads to bacterial phagocytosis, the initiation of immune responses as well as the activation of numerous cellular processes such as apoptosis, antigen processing/presentation, inflammasome activation, phagosome maturation, and autophagy. The interaction between TLR and Mtb leads to phagocyte activation without immediate ingestion of mycobacteria. Recognition of specific mycobacterial structures, such as lipoproteins 19 kDa, LM, LAM, and PIM was reported to be established by TLR2, which is consistent with observations that TLR2-mediated recognition is diminished by the presence of Lipooligosaccharide (LOS) in Mycobacterium canettii, the smooth variant of tubercle bacilli. It is noteworthy that loss of LOS production during the evolution of tuberculosis-causing mycobacteria has resulted in the rough colony morphology of Mtb strains, which apparently contributed to stronger recognition of Mtb by TLR2. Moreover, unmethylated CpG motifs in bacterial DNA were reported to be recognized by TLR9. These events induce a signaling cascade by stimulation of Myeloid Differentiation primary response protein 88 (MyD88) leading to activation and nuclear translocation of transcription factors, such as the Nuclear transcription Factor NF-κB and activation of the innate host defense such as the production of pro-inflammatory cytokines.
CLR/CTL are a family of membrane-bound calcium-dependent receptors that recognize carbohydrate-rich molecules. Among the CLR family, one of the most well-known receptors is the Mannose Receptor (MR), which recognizes mannose molecules/glycolipids present on Mtb’s surface such as LAM, ManLAM, and PIM. Stimulation through MR induces production of anti-inflammatory cytokines and fails to activate oxidative responses. Previous studies have shown that phagocytosis of mannosylated beads and/or MR-ManLAM interferes with phagosome maturation, highlighting the potential role of glycolipids in the intracellular survival of mycobacteria. A recent analysis of SNPs in the MRC1 gene within a Chinese population has suggested a possible association of selected SNPs and the susceptibility of individuals to pulmonary TB. Moreover, Mincle, Dectin-1 and -2, and Dendritic Cell immunoActivating Receptor (DCAR) also belong to the CLR sub-family and represent probably the most well-known CLR expressed on macrophages. The Mincle receptor specifically recognizes mycobacterial cord factor Trehalose-6,6-dimycolate (TDM), which likely represents the most abundant glycolipid in the mycobacterial cell wall. Ligation of TDM to Mincle induces several responses such as production of pro-inflammatory cytokines, generation of Th1/Th17 immune responses and induction of granuloma-genesis. It is known that Dectin-1 recognizes β-glucans in fungal pathogens but the precise Mtb’s PAMP is not known. It has been showed that Dectin-1 is important for the innate immunity recognition of Mtb and for inducing Th1 and Th17 responses, independently of TLR2 recognition. Dectin-2 has been recently shown to induce host immune responses against Mtb infection through the recognition of ManLAM. DCAR recognizes PIM to induce Th1 responses during Mtb infection. One other particular CRL/CTL, named DCSIGN/CD209, expressed by dendritic cells and macrophages recognizes conserved sugar motifs in a number of viruses, parasites, and bacteria, including Mtb.
Fc receptors and Complement Receptor (CR) are strongly expressed on surface of macrophages. CR3 plays a key role in the phagocytosis of Mtb by macrophages with recognition of Mtb polysaccharides or PIM.
Scavenger Receptors are expressed on the cell surface of mammalian monocytes and macrophages and recognized oxidized or acetylated lipoproteins. During Mtb infections, the Macrophage Receptor with Collagenous (MARCO) structure is the most studied. MARCO recognizes TDM and cooperates with TLR2 to induce the activation of the transcriptional factor NF-κB and secretion of pro-inflammatory cytokines.
Finally, cytosolic DNA sensors have also been described as PRR, which can recognize the presence of mycobacterial DNA in the cytosol. This process is dependent on phagosomal rupture induced by ESX-1 and is mediated via the cytosolic sensors cGAS or AIM2 (;;;; Figure 1).
Strategy 1: Interference with Phagosome Maturation
Macrophages are acting as the first line of defense against pathogenic invaders. After internalization, pathogens are trapped in a vacuole called phagosome, which immediately undergoes sequential fusion events to acquire microbicidal and degrading characteristics by a process called maturation. The dynamic of phagosome maturation is actively regulated by the network of Rab GTPases, proteins that sequentially drive the phagosome progression from early to later stages of maturation. Rab GTPases (Rab) contribute to the identity of the endosomal organelle (e.g., Rab5, early endosomes; Rab7, late endosome), regulating membrane-fusion events but also the sorting of protein and lipids through the recycling pathway. Thus, all along the usual maturation process, biological changes of the phagosome are characterized by the specific recruitment of Rab GTPase until the final fusion with lysosomes, which carry a set of hydrolytic enzymes that contribute to pathogen clearance. Recently other regulators of the phagosomal maturation, Rab34, Rab20, and the proneurotropin receptor sortilin, have been described as important for control and elimination of intracellular Mtb. Concurrently with the maturation process, the pH of phagosomes quickly drops from neutral to 5, through a high activity of a vesicular proton-pump ATPase (H+ V-ATPase). Phagosomal acidification is a prerequisite for intracellular bacterial clearance, as acidic pH is essential for the optimal activity of lysosomal digestive enzymes and for reactive oxygen species production. All along common trafficking pathways within macrophages, pathogens have to face multiple dangers such as exposure to cytosolic pattern recognition or danger receptors. The cytosolic lectin, Galectin8, notably recognizes damaged pathogen-containing vacuoles (including Mtb damaged phagosomes), and promotes their elimination by activating anti-bacterial autophagy (; Figure 1). Additionally, Ubiquitin ligases Parkin, Ubiquilin1, and Smurf1 recognize intracellular Mtb and enhance its clearance through an ubiquitin-mediated autophagy pathway (;; Figure 1).
To survive in this harsh environment, Mtb developed a wide range of strategies to counteract macrophages defenses. Mtb indeed triggers rapid interferences in phagosome functions by inhibiting the phagolysosome biogenesis. Unless the macrophage is activated by inflammatory cytokines, the mycobacterial vacuole fails to mature along the normal endocytic pathway, and retains features typical of an immature endosome. Just after macrophage uptake, mycobacterial phagosome transitory recruits early endosomal markers Rab5 and remains accessible to the marker of recycling endosome Rab11. In addition, Coronin1, also called TACO, is reported to be recruited and retained at the phagosomal surface where it activates calcium–calcineurin signaling to block the fusion of lysosomes with mycobacterial phagosomes (; Figure 1). Consistent with these immature characteristics, this organelle lacks the late endosomal and lysosomal markers Rab7 and CD63, as well as mature and active forms of various lysosomal hydrolases, including cathepsin D. Both bacterial ManLAM and the secreted phosphatase SapM have been shown to inhibit the activity of membrane trafficking regulatory lipid phosphatidylinositol 3-phosphate (PI3P), impairing the phagosomal acquisition of the lysosomal cargo and the delivery of hydrolytic enzyme from the Golgi network (,;; Figure 1).
Blockade of phagosomal acidification is also a key feature for the intracellular survival of pathogens. Consistently, Mtb has developed at least three different strategies aiming to inhibit H+ V-ATPase complex assembly and its subsequent fusion with the phagosomal membrane in order to stabilize the phagosomal pH between 6.2 and 6.5. Indeed, the phosphatase PtpA secreted by Mtb inhibits the assembly of H+ V-ATPase machinery by direct interaction with the subunits H of this complex. Additionally, interaction of TDM with C-type lectin receptor Mincle has been shown to delay phagosomal maturation and acidification. As parallel mechanism, we recently reported that Mtb depletes H+ V-ATPase from its phagosome by co-opting the function of a host immune regulator, i.e., cytokine-inducible SH2 containing protein (CISH), which selectively targets the H+ V-ATPase subunit A for ubiquitination and degradation by the proteasome (; Figure 1). The control of the pH is decisive not only for the survival of Mtb but also for the further processing of the mycobacterial phagosome. Indeed, early blockade of the acidification process is a pre-requisite for the ESX-1 dependent phagosomal rupture and the access of Mtb to the cytosol of the macrophage.
Strategy 2: Getting Access to the Cytosol
The intracellular localization of Mtb inside host cells has been studied since the 1970s. The seminal work of showed in mouse peritoneal macrophages that were infected with viable or non-viable Mtb and BCG strains that mycobacteria can be observed by electron microscopy (EM) inside phagosomes that have blocked the phagosome–lysosome fusion. In following years, further EM studies also observed Mtb outside the phagosome under certain conditions, whereas others could not observe mycobacteria in the cytosol by EM. Some of these disparities were thought to have been caused by differences in the EM conditions and protocols used. More recently, using sophisticated cryo-immunogold EM, have challenged the dogma of the exclusive intracellular localization of Mtb and have described the existence of cytosolic Mtb in THP-1 human macrophage-like cells at 4 days post-infection whereas the BCG strain did not show such a distribution. This result has been correlated with the function of the ESX/T7S system in Mtb, which is absent from BCG due to the ESX-1 deletion. However, given the situation that the suggested paradigm shift was entirely based on ultrastructural observations generated by electron microscopy, the presence of Mtb in the cytosol has remained controversial for some time. The development of a Fluorescent Resonance Energy Transfer (FRET) for detection of mycobacteria that have ruptured the phagosome and have established cytosolic contact has been an important advance to study this delicate and fascinating question. For that purpose, host cells are loaded with a chemical probe that is sensitive to FRET changes based on β-lactamase activity present on the surface of bacteria. The use of this FRET-based technology combined with automated fluorescent microscopy and multicolor quantitative cytofluorometry allowed to explore the role of ESX-1 in the induction of phagosomal rupture and more recently to show that Mtb induces phagosomal rupture in vivo (; Figure 1).
Based on the results from different groups using independent techniques, it thus became clear that the ESX-1/T7S system plays a primordial role for establishing cytosolic access of selected mycobacteria in host cells. However, very recently, in independent studies, additional mycobacterial factors have been identified that favor the access of Mtb to the cytosol. Indeed, it was found that cytosolic access of Mtb only occurs when the production and the export of the outer membrane lipids (DIM/PDIM) are intact. DIM/PDIM are key virulent lipids and play important roles in host-pathogen interaction. Their presence favors intracellular bacterial replication through arrest of phagosomal acidification by excluding the vacuolar proton-ATPase from the phagosomal membrane and they are also involved in the death of macrophages. The use of monoclonal antibodies against Galectin-3 and ubiquitinated proteins for identification of damaged phagosomal-membranes, in parallel to a FRET-based cytofluorometric approach for detection of phagosomal rupture, demonstrated the implication of DIM/PDIM in phagosomal rupture (Figure 1). This study showed that both the ESX-1 system and a functional DIM/PDIM production were required to cause phagosomal damage and rupture, which ultimately leads to host cell death. The implication of DIM/PDIM in this phenomenon has independently been confirmed by a study that investigated the DNA interaction and the regulon of a transcriptional repressor (Rv3167c), which was found to control the DIM/PDIM operon and to impact phagosomal escape. Additional confirmation came from a third study that carried out a multiparametric analysis, combining pathogen and host phenotypes, and found similar profiles for ESX-1 and DIM/PDIM loss-of-function mutants. Phospholipases have been described to play a role in the escape of the bacteria from phagosome to cytosol by acting together with pore-forming proteins such as listeriolysin from Listeria monocytogenes. The Mtb genome presents four phospholipases PlcA-D, whereby in the reference strain Mtb H37Rv PlcD has already been naturally inactivated by an IS6110-mediated deletion. The use of FRET-based cytofluorometry, however, showed that Plcs of Mtb do not seem to play a role in the phagosomal rupture as triple/quadruple Plc deletion mutants continued to generate positive signals in the phagosomal rupture assay, similar to wild-type strains.
Few studies report data on the implication of host factors involved in the induction of phagosomal rupture. A first result was obtained by the use of the FRET-cytofluorometry approach for the study of Mtb infection in macrophages carrying a non-functional nramp gene, encoding the Natural Resistance-Associated Macrophage Protein (Nramp-1), a phagosomal bivalent cation transporter implicated in phagosomal acidification and pH regulation. This approach showed that initial blockage of the acidification of the phagosome is necessary to allow bacteria to survive and to induce phagosomal rupture. Another host element that has been suggested in this context is the cytosolic phospholipase A2 (cPLA2). This enzyme plays a critical role in both phagosomal trafficking and export of cargo from the various endocytic comportments and permeabilizes the endosomal membrane in Mtb-infected macrophages. Treatment of Mtb-infected macrophages with an inhibitor of this enzyme induces a marked reduction of cytosolic bacteria as observed by EM.
Cytosolic contact of Mtb thus seems to be fundamental in mycobacterial host-pathogen interaction, influencing both the fate of the host cell and the bacteria. Indeed, the recognition of mycobacteria-associated patterns by the cytosolic receptors of the innate immunity determines innate and adaptive immune responses. Following steps exist: (i) DNA is sensed by cGAS, which synthesizes the second messenger cGAMP from ATP and GTP. cGAMP activates the Endoplasmic Reticulum (ER) associates Stimulator of IFN Genes (STING) and downstream TBK-1-IRF-3-IFN-β signaling axis (Figure 1). This effect leads to the expression of type I IFNs, such as IFN-α/β, which are thought to be disadvantageous to the host during Mtb infection, (ii) the cytosolic Mtb DNA may be sensed by AIM-2, which contributes partially to the activation of the NRLP3 inflammasome axis and release of mature IL-1β and IL-18, and (iii) the ESX-1-mediated cytosolic translocation of mycobacterial DNA results in the activation of TBK-1 which initiates the recruitment of LC3-II involved in autophagic activity (;; Figure 1). The last two points, in contrast to the first one, might be considered as more beneficial for the host. Thus, during infection, different and sometimes opposite responses govern the balance between the benefit for the mycobacteria and for the host. Nonetheless, during the infectious process mycobacteria are not necessarily constrained within the host cells, and may escape from the microbicidal environment of macrophages by disseminating inside the organism. It has been notably reported in the Zebra fish model that Mycobacterium marinum membrane Phenolic Glycolipids (PGL) trigger a STING-dependent secretion of monocyte chemoattractant protein 1 (MCP1; also called CCL2) by infected-resident macrophages, resulting in the recruitment of circulating monocytes and a subsequent transfer of the bacteria from tissue resident- to circulating macrophages.
Finally, in the context of vaccination, the induction of ESX-1-mediated cytosolic responses seems to be beneficial for increased protective efficacy provided by recombinant BCG strains over parental BCG strains.
Strategy 3: The Control of Host Cell Death
The control of host cell death allows Mtb to escape host defenses and to take the power on the pathogenesis control. For decades, host cell death upon Mtb-infection has been controversial and apoptosis cell death was considered as the only programmed cell death. Two main types of cell death are known for elimination of infected cells: (i) apoptosis or programmed cell death and (ii) necrosis.
From a morphological point of view, apoptosis is defined by plasma membrane bleeding, cell body shrinkage, nuclear condensation and fragmentation, and formation of apoptotic bodies, which are membrane-bound cell fragments rapidly phagocytosed by neighboring cells and resident phagocytes. From a biochemical point of view, apoptosis induces a decrease in mitochondrial inner transmembrane potential, activation of selective proteases, cleavage of chromosomal DNA, and various cellular proteins and translocation of phosphatidylserine from the inner to the outer plasma membrane. Apoptosis does occur via TNF-α activation and caspase 3 and 8 activation. Suppression of inflammation allows to limit tissue damage. Apoptosis of infected cells is considered as a benefit for the host. Indeed, it allows elimination of a favorable environment for replication of the pathogen, and provides an important source of bacterial antigens that can stimulate Mtb-specific T-cell immunity. Apoptosis has been directly linked to an increase CD8+ T-cell response via cross-presentation and enhances class II MHC-restricted antigen presentation.
Some Mtb genes have been reported to play a role in the inhibition or induction of host cell death, as for example sodA, encoding superoxide dismutase A, or nuoG, encoding the NADH dehydrogenase 1 subunit G. An Mtb gene well known for inducing host cell death is esxA, encoding EsxA, which has been described as a pro-apoptotic. The exact role of EsxA in this process remains unclear, but most probably it is the contribution to the access of Mtb to the host cytosol, which plays a main role. However, while the biological role of the ESX-1 system in the process remains fully valid, the function of recombinant EsxA as a putative membranolytic molecule was recently questioned, as the lytic activity of EsxA preparations expressed and purified from Escherichia coli lysates on red blood cells continued even after digestion with proteinase K, suggesting that some of the previously described pore-forming activity might be simply caused by a selected detergent used during the protein purification process. Further studies are needed to clarify the role of EsxA in the process.
In contrast to apoptosis, necrosis is characterized by loss of plasma membrane integrity, cytoplasmic organelles swelling such as mitochondria and cell nuclei, release of cytoplasmic and nuclear contents to the extracellular space, hydrolysis of chromatin and DNA and is caspase-independent cell death. It was previously thought that virulent Mtb inhibits apoptosis and triggers necrosis to evade innate immunity and thus to delay the initiation of adaptive immunity. On the contrary, attenuated Mtb induces macrophage apoptosis, which reduces bacterial viability. However, from different recent studies, it can be hypothesized that apoptosis induced by virulent Mtb favors dissemination of bacilli, while necrosis tends to enhance bacterial replication.
Colonization of macrophages by Mtb is a highly disputed process that depends on the ability of the pathogen to escape from macrophage killing and the capacity of the macrophages to control the bacterial proliferation.
Perspectives
It is clear that the interaction of Mtb with the macrophage has major impact on the outcome of infection, whereby both mycobacterial and host factors play important roles. The accumulated vast knowledge in recent years on this process might also turn out as important for developing potential new strategies in the fight against TB, concerning vaccines and host-directed therapies. For example, BCG complemented with the functional ESX-1 system of Mtb showed better efficacy to protect against disseminated TB in mice and guinea pigs. However, this recombinant strain named BCG::RD1 has also been shown to be more virulent than the wild-type BCG strain. As one possibility to reduce this enhanced virulence, introduction of selected mutations in the esxA gene of the cloned ESX-1 locus have shown some effect. Alternatively, the use of an ESX-1 secretion system taken from a less virulent mycobacterium than Mtb for the complementation of BCG seems also promising. Indeed, recombinant BCG expressing the ESX-1 system from Mycobacterium marinum, BCG::ESX-1Mmar, has been recently shown to be low virulent and more protective than parental BCG strains in different murine models of infection. This strain enhances NLRP3 inflammasome activation and induces type I IFN production and stronger CD8+ and CD4+ T-cell responses.
Using attenuated live Mtb strains as vaccines is another alternative approach, presenting the advantage that these strains naturally carry genetic regions encoding for important immunodominant antigens that might be absent from BCG in combination with sufficient safety, provided by the introduction of deletions in virulence genes. The live-attenuated MTBVAC is a good example. MTBVAC attenuation is based on two independent stable genetic deletions, without antibiotic resistance markers, introduced into phoP and fadD26, affecting the production and secretion of selected lipidic and proteic virulence factors of Mtb. MTBVAC presents promising features in preclinical animal models and is presently being evaluated in a phase I clinical trial in newborns in South Africa. Other attenuated Mtb strain, presently in preclinical development with promising results in murine infection models, is the MtbΔppe25-pe19 strain, in which selected PE and PPE proteins of the ESX-5 secretion system have been deleted, but which retains an intact ESX-1 secretion system.
Concerning drug treatment of TB, most of the drugs used today date from the 1950s to 1960s, with a few exceptions, such as bedaquiline, a recently discovered ATP synthase inhibitor that is currently used successfully in drug regimens against MDR-TB. However, additional identification of new active anti-TB drugs is urgently needed. In this perspective, it should be mentioned that remarkable progress has been made in developing new screening approaches that can simultaneously evaluate the anti-bacterial potency and the non-cytotoxic properties of small molecule inhibitors in the intracellular environment of Mtb-infected macrophages. Moreover, targeting of mycobacterial virulence factors might also be a possibility to find alternative treatment approaches. As one example, screening of a compound library recently allowed molecules to be identified that target the ESX-1 secretion system of Mtb and/or the global two-component regulator PhoP/R which among many other virulence factors also regulates ESX-1-mediated secretion.
Host-directed therapy (HDT) to treat TB is a relatively new and promising concept that starts to arouse a great interest from the scientific community. Instead of targeting Mtb compounds directly, HDT targets the host response, such as the modulation of host inflammatory pathways to reduce inflammation and lungs tissue damages, augmenting cellular anti-microbial mechanisms. In the case of TB-HIV co-infection, HDT may reduce the risk of interaction with antiretroviral drugs. In the case of MDR or XDR-TB, HDT could be added to anti-TB treatment to increase the capacity of the host system to eliminate mycobacteria or to limit tissue damage due to the infection. For instance, in association with anti-TB drugs, statins, a family of inhibitors of HMG-CoA reductase, originally used to lower cholesterol levels in patients, drastically enhance the efficacy of first-line TB treatments in macrophages and in vivo models. Moreover, Vitamin D treatment has been suggested to promote the expression anti-microbial peptide Cathelicidin by macrophages, and thus lowering of the intracellular survival of Mtb.
Some HDTs are in clinical human trials or preclinical animal studies, such as anti-inflammatory therapies, modulation of inflammation by phosphodiesterase inhibitors, eicosanoid modulation, non-steroidal anti-inflammatory drugs, high-dose vitamin D application, alteration of lipid metabolism, as well as new HDT that targets autophagy. Autophagy appears to be a promising pathway to target for the development of drugs. Interestingly, anti-mycobacterial activities of both statins and Cathelicidin have been correlated with their ability to enhance the autophagy pathway. As such, HDT opens new avenues for individualized TB therapies.
Conclusion
We have discussed a selection of amazing strategies of Mtb and host cells in their battle about survival and death in host-pathogen interaction that remains a highly interesting research domain. Driven by an advancing technical progress, many new insights were obtained in recent years and have often led to changes in long-lasting hypotheses and theories, a finding which gives hope that in the upcoming years more progress will further contribute to the knowledge how to better fight Mtb and reduce the burden of TB in the world.
Author Contributions
All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References 132
- 1.
Abdallah A. M. Gey Van Pittius N. C. Champion P. A. Cox J. Luirink J. Vandenbroucke-Grauls C. M. (2007 ). Type VII secretion system of mycobacteria show the way. Nat. Rev. Microbiol. 5 883–891.
Not in our library10.1038/nrmicro1773
- 2.
Aguilo J. Alonso H. Uranga S. Marinova D. Arbues A. De Martino A. (2013 ). ESX-1-induced apoptosis is involved in cell-to-cell spread of Mycobacterium tuberculosis. Cell Microbiol 15 1994–2005.
Not in our library10.1111/cmi.12169
- 3.
Aguilo N. Gonzalo-Asensio J. Alvarez-Arguedas S. Marinova D. Gomez A. B. Uranga S. (2017 ). Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis. Nat. Commun. 8:16085.
Not in our library10.1038/ncomms16085
- 4.
Andries K. Verhasselt P. Guillemont J. Gohlmann H. W. Neefs J. M. Winkler H. (2005 ). A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307 223–227.
Not in our library10.1126/science.1106753
- 5.
Armstrong J. A. Hart P. D. (1971 ). Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J. Exp. Med. 134 713–740.
Not in our library10.1084/jem.134.3.713
- 6.
- 7.
Astarie-Dequeker C. N’diaye E. N. Le Cabec V. Rittig M. G. Prandi J. Maridonneau-Parini I. (1999 ). The mannose receptor mediates uptake of pathogenic and nonpathogenic mycobacteria and bypasses bactericidal responses in human macrophages. Infect. Immun. 67 469–477.
Not in our library10.1128/iai.67.2.469-477.1999
- 8.
Augenstreich J. Arbues A. Simeone R. Haanappel E. Wegener A. Sayes F. (2017 ). ESX-1 and phthiocerol dimycocerosates of Mycobacterium tuberculosis act in concert to cause phagosomal rupture and host cell apoptosis. Cell Microbiol. 19:e12726.
Not in our library10.1111/cmi.12726
- 9.
Axelrod S. Oschkinat H. Enders J. Schlegel B. Brinkmann V. Kaufmann S. H. (2008 ). Delay of phagosome maturation by a mycobacterial lipid is reversed by nitric oxide. Cell Microbiol. 10 1530–1545.
Not in our library10.1111/j.1462-5822.2008.01147.x
- 10.
Bafica A. Scanga C. A. Feng C. G. Leifer C. Cheever A. Sher A. (2005 ). TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J. Exp. Med. 202 1715–1724.
Not in our library10.1084/jem.20051782
- 11.
- 12.
Barry C. E. III Boshoff H. I. Dartois V. Dick T. Ehrt S. Flynn J. (2009 ). The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7 845–855.
Not in our library10.1038/nrmicro2236
- 13.
Beckham K. S. Ciccarelli L. Bunduc C. M. Mertens H. D. Ummels R. Lugmayr W. (2017 ). Structure of the mycobacterial ESX-5 type VII secretion system membrane complex by single-particle analysis. Nat. Microbiol. 2:17047.
Not in our library10.1038/nmicrobiol.2017.1047
- 14.
Behar S. M. Divangahi M. Remold H. G. (2010 ). Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? Nat. Rev. Microbiol. 8 668–674.
Not in our library10.1038/nrmicro2387
- 15.
Behar S. M. Martin C. J. Booty M. G. Nishimura T. Zhao X. Gan H. X. (2011 ). Apoptosis is an innate defense function of macrophages against Mycobacterium tuberculosis. Mucosal Immunol. 4 279–287.
Not in our library10.1038/mi.2011.3
- 16.
Boritsch E. C. Frigui W. Cascioferro A. Malaga W. Etienne G. Laval F. (2016 ). pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence. Nat. Microbiol. 1:15019.
Not in our library10.1038/nmicrobiol.2015.19
- 17.
- 18.
Bottai D. Di Luca M. Majlessi L. Frigui W. Simeone R. Sayes F. (2012 ). Disruption of the ESX-5 system of Mycobacterium tuberculosis causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation. Mol. Microbiol. 83 1195–1209.
Not in our library10.1111/j.1365-2958.2012.08001.x
- 19.
Bottai D. Frigui W. Clark S. Rayner E. Zelmer A. Andreu N. (2015 ). Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system. Vaccine 33 2710–2718.
Not in our library10.1016/j.vaccine.2015.03.083
- 20.
Bottai D. Serafini A. Cascioferro A. Brosch R. Manganelli R. (2014 ). Targeting type VII/ESX secretion systems for development of novel antimycobacterial drugs. Curr. Pharm. Des 20 4346–4356.
Not in our library10.2174/1381612819666131118170717
- 21.
- 22.
Brennan P. J. Nikaido H. (1995 ). The envelope of mycobacteria. Annu. Rev. Biochem. 64 29–63.
Not in our library10.1146/annurev.bi.64.070195.000333
- 23.
Cambier C. J. Falkow S. Ramakrishnan L. (2014 ). Host evasion and exploitation schemes of Mycobacterium tuberculosis. Cell 159 1497–1509.
Not in our library10.1016/j.cell.2014.11.024
- 24.
- 25.
Chalut C. (2016 ). MmpL transporter-mediated export of cell-wall associated lipids and siderophores in mycobacteria. Tuberculosis 100 32–45.
Not in our library10.1016/j.tube.2016.1006.1004
- 26.
Chen J. M. Pojer F. Blasco B. Cole S. T. (2010 ). Towards anti-virulence drugs targeting ESX-1 mediated pathogenesis of Mycobacterium tuberculosis. Drug Discov. Today 7 e25–e31.
Not in our library10.1016/j.ddmec.2010.09.002
- 27.
- 28.
Clemens D. L. Horwitz M. A. (1995 ). Characterization of the Mycobacterium tuberculosis phagosome and evidence that phagosomal maturation is inhibited. J. Exp. Med. 181 257–270.
Not in our library10.1084/jem.181.1.257
- 29.
Cole S. T. Brosch R. Parkhill J. Garnier T. Churcher C. Harris D. (1998 ). Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393 537–544.
Not in our library10.1038/31159
- 30.
Collins A. C. Cai H. Li T. Franco L. H. Li X. D. Nair V. R. (2015 ). Cyclic GMP-AMP synthase is an innate immune DNA sensor for Mycobacterium tuberculosis. Cell Host Microbe 17 820–828.
Not in our library10.1016/j.chom.2015.05.005
- 31.
Conrad W. H. Osman M. M. Shanahan J. K. Chu F. Takaki K. K. Cameron J. (2017 ). Mycobacterial ESX-1 secretion system mediates host cell lysis through bacterium contact-dependent gross membrane disruptions. Proc. Natl. Acad. Sci. U.S.A. 114 1371–1376.
Not in our library10.1073/pnas.1620133114
- 32.
Cossart P. (2011 ). Illuminating the landscape of host-pathogen interactions with the bacterium Listeria monocytogenes. Proc. Natl. Acad. Sci. U.S.A. 108 19484–19491.
Not in our library10.1073/pnas.1112371108
- 33.
Daffe M. Crick D. C. Jackson M. (2014 ). Genetics of capsular polysaccharides and cell envelope (Glyco)lipids. Microbiol. Spectr. 2 14.
Not in our library10.1128/microbiolspec.mgm2-0021-2013
- 34.
Dallenga T. Repnik U. Corleis B. Eich J. Reimer R. Griffiths G. W. (2017 ). M. tuberculosis-induced necrosis of infected neutrophils promotes bacterial growth following phagocytosis by macrophages. Cell Host Microbe 22 519–530.e3.
Not in our library10.1016/j.chom.2017.09.003
- 35.
Davis J. M. Ramakrishnan L. (2009 ). The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 136 37–49.
Not in our library10.1016/j.cell.2008.11.014
- 36.
Diacon A. H. Pym A. Grobusch M. Patientia R. Rustomjee R. Page-Shipp L. (2009 ). The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360 2397–2405.
Not in our library10.1056/nejmoa0808427
- 37.
Dinadayala P. Lemassu A. Granovski P. Cerantola S. Winter N. Daffe M. (2004 ). Revisiting the structure of the anti-neoplastic glucans of Mycobacterium bovis Bacille Calmette-Guerin. Structural analysis of the extracellular and boiling water extract-derived glucans of the vaccine substrains. J. Biol. Chem. 279 12369–12378.
Not in our library10.1074/jbc.m308908200
- 38.
Ehrt S. Schnappinger D. (2009 ). Mycobacterial survival strategies in the phagosome: defence against host stresses. Cell Microbiol. 11 1170–1178.
Not in our library10.1111/j.1462-5822.2009.01335.x
- 39.
Fratti R. A. Backer J. M. Gruenberg J. Corvera S. Deretic V. (2001 ). Role of phosphatidylinositol 3-kinase and Rab5 effectors in phagosomal biogenesis and mycobacterial phagosome maturation arrest. J. Cell Biol. 154 631–644.
Not in our library10.1083/jcb.200106049
- 40.
Fratti R. A. Chua J. Vergne I. Deretic V. (2003 ). Mycobacterium tuberculosis glycosylated phosphatidylinositol causes phagosome maturation arrest. Proc. Natl. Acad. Sci. U.S.A. 100 5437–5442.
Not in our library10.1073/pnas.0737613100
Cited by papers we hold 4
- Phenotypic adaptation of Mycobacterium tuberculosis to host-associated stressors that induce persister formation · 2022Not checked
- Macrophage: A Cell With Many Faces and Functions in Tuberculosis · 2022No notice
- Functions of ROS in Macrophages and Antimicrobial Immunity · 2021No notice
- Immune Response to Mycobacterium tuberculosis: A Narrative Review · 2019No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.